Regulatory Novo Nordisk preps filings for sickle cell drug etavopivat PharmaphorumNovo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.RegulatoryHematologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease. RegulatoryHematologyRead full story Post navigation Previous: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new dataNext: Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
